SeaStar Medical Q1 Call: ICU Traders Await Cash Burn, Pipeline

Without the actual Q1 numbers, the watchpoints for ICU are well-defined. The company ended 2025 with a thin cash balance and has relied on equity-linked financing. Traders will be listening for any update on cash burn, which in prior quarters ran at several million dollars. The revenue line is still nascent; any mention of initial SCD unit sales or hospital contracts would be a material signal. Conversely, a lack of revenue commentary would reinforce the pre-revenue risk.

• Cash position: The call is expected to clarify whether the company has enough runway to fund operations through the next clinical readout or if another capital raise is imminent.
• SCD placements: Even a handful of pediatric centers adopting the device would validate the commercial thesis. The call may provide an update on the number of sites trained or orders received.
• Adult AKI trial: The pivotal study for the larger indication is the long-term value driver. Any timeline update, enrollment progress, or FDA interaction would move the stock.
• Partnerships or licensing: SeaStar has previously discussed seeking a strategic partner for the adult program. A deal would transform the balance sheet.

ICU shares have been volatile, often moving on regulatory headlines rather than fundamentals. The Q1 call is a chance for management to reset expectations and demonstrate that the SCD is more than a science project. The stock's reaction will likely hinge on whether the tone on commercialization is concrete or aspirational.

Next Catalyst: Full Transcript and 10-Q Filing

The incomplete transcript leaves the market in a holding pattern. The full call recording and the subsequent 10-Q filing will provide the actual revenue, expense, and cash figures. For traders, the immediate decision point is whether to position ahead of that disclosure. A leaner cash burn or a surprise revenue entry could spark a relief rally; a larger-than-expected cash outflow without a clear funding path would pressure the stock further.

SeaStar Medical's story is binary in the near term. The Q1 call, once fully digested, will either confirm that the SCD is gaining commercial traction or reinforce that the company is still in a pre-revenue, cash-consuming phase. The next concrete marker is the SEC filing, which will put hard numbers behind the management commentary.